| Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up J Tutzauer, M Sjöström, E Holmberg, P Karlsson, F Killander, ... British journal of cancer 126 (8), 1145-1156, 2022 | 30 | 2022 |
| Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral … J Tutzauer, M Sjöström, PO Bendahl, L Rydén, M Fernö, ... PloS one 15 (4), e0231786, 2020 | 22 | 2020 |
| Ligand-Independent G Protein–Coupled Estrogen Receptor/G Protein–Coupled Receptor 30 Activity: Lack of Receptor-Dependent Effects of G-1 and 17β-Estradiol J Tutzauer, EG de Valdivia, K Swärd, IA Eilard, S Broselid, R Kahn, B Olde, ... Molecular Pharmacology 100 (3), 271-282, 2021 | 17 | 2021 |
| Mast cell proteases tryptase and chymase induce migratory and morphological alterations in bronchial epithelial cells F Berlin, S Mogren, J Tutzauer, CK Andersson International Journal of Molecular Sciences 22 (10), 5250, 2021 | 15 | 2021 |
| Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII: 2 trial C Lundgren, J Tutzauer, SE Church, O Stål, M Ekholm, C Forsare, ... Breast Cancer Research 25 (1), 110, 2023 | 4 | 2023 |
| Gene expression in metastatic breast cancer–patterns with prognostic potential in primary tumors and metastatic tissue J Tutzauer, AM Larsson, K Aaltonen, C Bergenfelz, PO Bendahl, L Rydén | 2 | 2023 |
| Gene expression in metastatic breast cancer—patterns in primary tumors and metastatic tissue with prognostic potential J Tutzauer, AM Larsson, K Aaltonen, C Bergenfelz, PO Bendahl, L Rydén Frontiers in Molecular Biosciences 10, 1343979, 2024 | 1 | 2024 |
| G protein-coupled estrogen receptor (GPER)/GPR30 forms a complex with the β1-adrenergic receptor, a membrane-associated guanylate kinase (MAGUK) scaffold protein, and protein … J Tutzauer, DS Serafin, T Schmidt, B Olde, KM Caron, ... Archives of Biochemistry and Biophysics 752, 109882, 2024 | 1 | 2024 |
| 300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with> 20-year … J Tutzauer, JKJ De Vos, A Nordenskjöld, BA Nordenskjöld, T Fornander, ... Annals of Oncology 35, S340, 2024 | | 2024 |
| 409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up JKJ De Vos, J Tutzauer, A Nordenskjöld, BA Nordenskjöld, T Fornander, ... Annals of Oncology 35, S390, 2024 | | 2024 |
| Abstract PO4-05-14: Gene expression in metastatic breast cancer–patterns and prognostic potential J Tutzauer, AM Larsson, K Aaltonen, PO Bendahl, C Bergenfelz, ... Cancer Research 84 (9_Supplement), PO4-05-14-PO4-05-14, 2024 | | 2024 |
| Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit T Engström, M Ekholm, M Fernö, C Lundgren, B Nordenskjöld, O Stål, ... Acta Oncologica 63, 2024 | | 2024 |
| Prediction of Tamoxifen Benefit in Premenopausal Breast Cancer Patients Evaluated by Three Methods for Determination of Hormone Receptor Status T Engström, M Ekholm, M Fernö, C Lundgren, B Nordenskjöld, O Stål, ... | | 2023 |
| GPR30 in breast cancer-from molecular mechanisms to clinical outcome J Tutzauer | | 2022 |
| Abstract P6-05-09: G protein-coupled estrogen receptor expressed in the plasma membrane is associated with worse breast cancer outcome, but does not contribute to tamoxifen … J Tutzauer, M Sjöström, PO Bendahl, L Rydén, M Fernö, F Leeb-Lundberg, ... Cancer Research 80 (4_Supplement), P6-05-09-P6-05-09, 2020 | | 2020 |
